# Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

> **NCT06413017** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- HCC

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** ICIs(Immune checkpoint inhibitors)

## Key facts

- **NCT ID:** NCT06413017
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-31
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413017, "Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06413017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*